Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Capital Expenditures (2022 - 2025)

Envoy Medical recorded quarterly Capital Expenditures of $172000.0 in Q4 2025, up 17100.0% quarter-over-quarter from $1000.0 in Q2 2025, and up 132.21% year-over-year from $74071.0 in Q4 2024.

Envoy Medical's Capital Expenditures history runs 4 years deep, the most recent figure standing at $172000.0 for Q4 2025.

  • In Q4 2025, Capital Expenditures rose 132.21% year-over-year to $172000.0; the TTM figure through Dec 2025 stood at $179000.0 (down 81.73% YoY), while the FY2025 annual figure was $179000.0, down 81.73% from the prior year.
  • Capital Expenditures came in at $172000.0 for Q4 2025 at Envoy Medical, up from $1000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q3 2024 to a low of -$534000.0 in Q4 2024.
  • A 4-year average of $112750.0 and a median of $50000.0 in 2022 frame the typical range for Capital Expenditures.
  • On a YoY basis, Capital Expenditures climbed as much as 2154.55% in 2024 and fell as far as 2642.86% in 2024.
  • Envoy Medical's Capital Expenditures stood at $41000.0 in 2022, then slumped by 48.78% to $21000.0 in 2023, then slumped by 2642.86% to -$534000.0 in 2024, then surged by 132.21% to $172000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods registered $172000.0, $1000.0, and $6000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 399.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 166.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 444.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 177.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 64.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -85.46 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 76.60 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 86.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 90.20 Mn
10 Envoy Medical 48.11 Mn 22.86 Mn -274,000.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 172,000.00
Dec 31, 2025 172,000.00
Jun 30, 2025 1,000.00
Jun 30, 2025 1,000.00
Mar 31, 2025 6,000.00
Mar 31, 2025 6,000.00
Dec 31, 2024 -534,000.00
Dec 31, 2024 -534,000.00
Sep 30, 2024 1.16 Mn
Sep 30, 2024 1.16 Mn
Jun 30, 2024 248,000.00
Jun 30, 2024 248,000.00
Mar 31, 2024 109,000.00
Mar 31, 2024 109,000.00
Dec 31, 2023 21,000.00
Dec 31, 2023 21,000.00
Sep 30, 2023 62,000.00
Sep 30, 2023 62,000.00
Jun 30, 2023 11,000.00
Jun 30, 2023 11,000.00
Mar 31, 2023 59,000.00
Mar 31, 2023 59,000.00
Dec 31, 2022 41,000.00
Dec 31, 2022 41,000.00